Form 8-K ARVINAS, INC. For: Feb 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Arvinas Inc. (ARVN) PT Lowered to $81 at H.C. Wainwright
February 12, 2025 6:44 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $81.00 (from $87.00) while maintaining a Buy rating.
The analyst comments "VERITAC-2 trial design differences can impact mPFS outcome. As Arvinas plans to share the Phase 3 data from the vepdeg monotherapy trial in 1Q 2025, we remain encouraged that a CBR of 37.1% and 38.9% in 200 mg QD and 500 mg QD is impressive, and we consider it might result in a competitive mPFS in comparison to the EMERALD data of 3.8 months (elacestrant arm) versus 1.9 months (control).... More
